AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 42 min read$STE

Breeden Richard C sold $310K of STE

Breeden Richard C sold 1,481 shares of STERIS plc (STE) at $209.51 ($0.31M total) on 2026-06-02.

Original reporting
SEC EDGAR · Breeden Richard C
Published Jun 4, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 4, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$STE
Neutral
high confidence
Mentioned
$STE
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STENeutralLow
01

Why it matters

The disclosure updates insider activity records but does not introduce new company fundamentals (earnings, guidance, deals, litigation, or regulatory actions).

02

Market read

Primarily a sentiment/positioning datapoint for STE; likely limited trading impact absent additional catalysts.

03

What to watch

Insider sales often occur for non-informational reasons (taxes, planned diversification, personal liquidity), and the article provides no follow-on guidance or performance change.

Relevance 4/10Novelty 3/10Timing: Filed 2026-06-04; sale occurred 2026-06-02.

Background

The article is an SEC Form 4 insider transaction disclosure for STERIS plc, reported by a director.

Company-level read

Ticker impact

$STENeutralHigh confidence
Context

STERIS director Richard C Breeden sold 1,481 shares in an open-market transaction at ~$209.51 on 2026-06-02, disclosed via Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived and sentiment-driven.

Evidence & confidence

The filing reports a routine Form 4 sale with no 10b5-1 plan stated and no accompanying company-specific operational or financial news.

Market effects

Sector

Minimal; single-company insider transaction without sector-wide implications.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is open-market and the filing lacks a stated 10b5-1 plan, traders may overinterpret it; it could still be routine liquidity or diversification.

Key entities

  • issuer
    STERIS plc

    Subject of the SEC Form 4 insider sale disclosure.

  • insider
    Breeden Richard C

    Director who sold 1,481 shares on 2026-06-02.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

STE insider trading history →

Related articles

OCT 18
$UNHMed

Notable healthcare headlines for the week: J&J, UnitedHealth, and CVS in focus

UnitedHealth (UNH) raised 2026 earnings guidance after Q3 results beat estimates, with adjusted EPS at $4.69. Johnson & Johnson (JNJ) also raised full-year guidance. Roche (RHHBY) signed a $1.16B deal for an obesity drug. STERIS (STE) to acquire Xodus Medical for $2.1B. Iambic Therapeutics (IAM) debuted with a 10% rise. CVS (CVS) agreed to pay $315M over opioid prescription allegations.

tradingview.com3 min
OCT 13
$STEHighAI 9/10

Steris Announces Major Acquisition of Xodus Medical, Inc.

STERIS (STE) agreed to acquire Xodus Medical, Inc. for $2.1B in cash, with up to $150M in earnout payments, subject to regulatory approval. The deal is expected to close by December 31, 2026, and will be financed primarily with debt. Analysts rate STE stock as Buy with a $269 price target, citing strong financial quality and growth guidance.

tipranks.com2 min
OCT 13
$STEHighAI 9/10

Steris inks $2.1B Xodus buyout to expand consumables portfolio

Steris (STE) agreed to acquire Xodus Medical for $2.1B, expecting $245M in annual sales. The deal expands Steris' healthcare consumables portfolio, with debt financing and potential performance-based payouts. Analysts expect earnings per share growth from 2027. Steris aims to close the deal this year, following its M&A strategy focused on hospital-related technology.

finance.yahoo.com2 min
OCT 13
$STEHighAI 9/10

Steris outlays $2.1bn to acquire Xodus Medical

Steris (STE) agreed to acquire Xodus Medical, a privately held surgical safety solutions developer, for $2.1 billion. The deal will expand Steris's healthcare consumables portfolio, including Xodus's surgical products like the Pink Pad. Steris expects the acquisition to complement its offerings and drive growth, with Xodus projecting $245 million in 2026 revenue. Steris's healthcare consumables segment grew 10% year-on-year in Q2 2026.

finance.yahoo.com2 min